New Generation Technologies

Ark Surgical is a medical device start-up focused on enhancing laparoscopic surgery through innovative solutions. The company has developed LapBox, a containment system designed to safely remove large internal organs via a laparoscopic keyhole incision. This device significantly reduces the risk of cancerous tissue dispersion during minimally invasive procedures, particularly in women's health. The first version of LapBox has received FDA clearance, with a second iteration in development. By enabling surgeons to perform safe organ removals without the complications associated with traditional tissue morcellation, Ark Surgical aims to improve patient outcomes in laparoscopic surgeries.

Bankin' is a mobile application focused on simplifying money management for its users. With a user base of over 1.5 million across France, England, Spain, and Germany, the company prides itself on being the leading independent money management solution in Europe. The app utilizes intelligent algorithms and human coaching to deliver personalized advice related to savings, credit, and insurance, ensuring that customers can manage their finances efficiently. Bankin' emphasizes its commitment to transparency and simplicity, allowing users to concentrate on their priorities without the complications often associated with financial management. By remaining independent of traditional banking institutions, Bankin' aims to provide unbiased guidance tailored to the individual needs of its customers.

CartiCure is a MedTech company focused on tissue engineering, specifically developing technology for repairing cartilage defects. Its innovative platform generates original hyaline cartilage-producing cells that can be transplanted into damaged joints, effectively addressing both small and large lesions in articular cartilage. This technology aims to assist patients suffering from knee cartilage damage, often resulting from traumatic injuries, by providing an advanced solution for cartilage repair.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions affecting infants. Established in 2003 and based in Ramat-Gan, Israel, the company is advancing clinical programs, including NTRA-2112, which aims to treat intestinal malabsorption in preterm infants by reducing enteral nutrition intolerance and improving growth metrics, as well as shortening hospital stays. Another significant product in development is NTRA-9620, designed for short bowel syndrome, which promotes bowel adaptation post-surgery and minimizes the need for parenteral nutrition. Nutrinia's offerings primarily consist of oral insulin formulations that facilitate gut adaptation and rehabilitation, thereby enhancing nutritional absorption in infants.